Immunotherapy injected directly into fluid cavities shows promise for pancreatic cancer
NCT ID NCT07230301
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether putting an immunotherapy drug called adebrelimab directly into the chest or belly can help control cancer-related fluid buildup in people with advanced pancreatic cancer. About 20 participants will receive the drug along with standard care. The goal is to see if this approach improves survival and reduces fluid buildup.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to
If it works, this could offer a new way to control painful fluid buildup in the chest or belly for people with advanced pancreatic cancer.
What could go wrong
This is a small, early-phase trial with only 20 people, so results may not apply to everyone. The drug may cause side effects like fatigue or nausea, and it is not yet proven to extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.